Testing blood clotting in stroke patients on blood thinners
Official title: Qualitative Coagulation Testing With the CoaguChek(R) Pro II Point-of-Care Test System and aPTT Test Cards in Patients Before and After First Intake of Direct Oral Anticoagulants
Run by University Hospital Tuebingen · NCT04679298 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a quick blood test to see if it can accurately measure blood thinner levels in stroke patients who can't share their medication history.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | University Hospital Tuebingen Academic / other |
| Locations | 1 site (Tuebingen) |
| Trial ID | NCT04679298 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older who are stroke patients recently started on DOAC therapy for secondary prevention.
✕Probably not a fit
Patients who have taken vitamin K antagonists or other anticoagulants shortly before the study or those with abnormal coagulation values will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of CoaguChek point-of-care testing to measure the levels of direct oral anticoagulants (DOACs) in stroke patients. It aims to determine the correlation between the test results and the actual plasma levels of DOACs, which are crucial for making timely treatment decisions in emergency situations. The study focuses on patients who have recently started anticoagulation therapy and may not be able to communicate their medication history due to their condition. By providing rapid diagnostic information, the study seeks to improve patient outcomes in acute stroke scenarios.
Why it matters
Potential benefit: If successful, this study could enhance the ability to quickly assess anticoagulant levels in stroke patients, leading to more effective and timely treatment decisions.
How similar studies have gone: Previous studies have shown promising results with point-of-care testing for anticoagulants, but this specific approach with CoaguChek is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Stroke patients, who were newly started on oral anticoagulation with apixaban, edoxaban, dabigatran or rivaroxaban for secondary prevention of thromboembolic events * informed consent Exclusion Criteria: * Vitamin K antagonists ≤ 14 days prior to study participation * Prior DOAC intake ≤ 72 hours * Low-molecular weight heparin ≤ 24 hours * Unfractionated heparin ≤ 12 hours * Heparinoids (e.g. Fondaparinux) ≤ 72 hours * Abnormal coagulation values at baseline (Quick \< 70% or activated thromboplastin time (aPTT) \> 40sec.) * History of coagulopathy
Where it's running
-
University Hospital Tuebingen
Tuebingen, Germany Recruiting
Study contacts
- Study coordinator: Sven Poli, MD MSc
- Email: sven.poli@uni-tuebingen.de
- Phone: +49(0)707129
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating the safety and effectiveness of edoxaban and rivaroxaban for treating cerebral venous thrombosis in Chinese patients
This study is testing whether two blood thinners, edoxaban and rivaroxaban, are safe and effective for treating cerebral venous thrombosis in Chinese patients aged 18 to 80.
-
Digital cognitive check after a stroke in people with severe disability
This study tests how well a digital cognitive assessment app (TuCAN-App) can track recovery in adults who had a major stroke and were severely disabled.
-
Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence
This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.
-
Detecting cardiac amyloidosis in people with severe aortic valve narrowing
This study tests non-invasively whether imaging tests can find heart amyloidosis in patients with severe aortic stenosis who are being evaluated for valve replacement.
-
Low-thermal Argon Plasma Devitalization for CIN2 Treatment
This study tests whether a low-thermal argon plasma treatment can heal CIN2 on the cervix better than a sham procedure or active surveillance in women aged 18–40.
-
Real-time AI detection of surgical smoke during endoscopic laparoscopic procedures
This pilot will test whether an AI system can detect surgical smoke in real time from endoscopic video during laparoscopic procedures that use high-frequency surgical devices.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.